Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:FULC NASDAQ:KMDA NASDAQ:PYXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.72-0.9%$4.01$1.25▼$4.98$472.38M1.83893,535 shs332,192 shsFULCFulcrum Therapeutics$7.05+2.5%$7.64$5.28▼$15.74$467.61M3.02956,689 shs145,845 shsKMDAKamada$8.40+1.7%$8.50$6.50▼$9.35$484.81M0.8667,566 shs14,159 shsPYXSPyxis Oncology$2.46+8.6%$1.59$0.97▼$5.55$154.17M1.43622,887 shs861,033 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-2.33%-0.19%+1.07%-5.88%+201.20%FULCFulcrum Therapeutics-3.23%-3.51%-12.13%-29.36%+36.13%KMDAKamada-0.24%+1.47%+0.12%+0.61%+21.29%PYXSPyxis Oncology-1.74%+32.94%+54.79%+49.67%+112.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.72-0.9%$4.01$1.25▼$4.98$472.38M1.83893,535 shs332,192 shsFULCFulcrum Therapeutics$7.05+2.5%$7.64$5.28▼$15.74$467.61M3.02956,689 shs145,845 shsKMDAKamada$8.40+1.7%$8.50$6.50▼$9.35$484.81M0.8667,566 shs14,159 shsPYXSPyxis Oncology$2.46+8.6%$1.59$0.97▼$5.55$154.17M1.43622,887 shs861,033 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-2.33%-0.19%+1.07%-5.88%+201.20%FULCFulcrum Therapeutics-3.23%-3.51%-12.13%-29.36%+36.13%KMDAKamada-0.24%+1.47%+0.12%+0.61%+21.29%PYXSPyxis Oncology-1.74%+32.94%+54.79%+49.67%+112.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.50Moderate Buy$8.00115.34% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$19.00169.47% UpsideKMDAKamada 3.00Buy$13.0054.82% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83178.34% UpsideCurrent Analyst Ratings BreakdownLatest PYXS, KMDA, FULC, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.005/5/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.005/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.004/21/2026FULCFulcrum Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/24/2026PYXSPyxis Oncology Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.003/24/2026PYXSPyxis Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/23/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $8.003/12/2026KMDAKamada BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/11/2026KMDAKamada Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$11.002/24/2026FULCFulcrum Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$17.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M5.81N/AN/A($1.70) per share-2.19FULCFulcrum Therapeutics$80M5.87N/AN/A$5.00 per share1.41KMDAKamada$180.46M2.68$0.62 per share13.56$4.68 per share1.79PYXSPyxis Oncology$13.86M11.13N/AN/A$0.86 per share2.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%N/AFULCFulcrum Therapeutics-$74.88M-$1.15N/AN/AN/AN/A-27.80%-26.32%N/AKMDAKamada$20.20M$0.3524.0914.230.6311.19%7.72%5.39%5/13/2026 (Estimated)PYXSPyxis Oncology-$79.62M-$1.29N/AN/AN/AN/A-101.77%-69.81%5/8/2026 (Estimated)Latest PYXS, KMDA, FULC, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026PYXSPyxis Oncology-$0.35N/AN/AN/A$10.94 millionN/A5/13/2026Q1 2026KMDAKamada$0.12N/AN/AN/A$46.72 millionN/A5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 million4/27/2026Q1 2026FULCFulcrum Therapeutics-$0.31-$0.25+$0.06-$0.25N/AN/A3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/11/2026Q4 2025KMDAKamada$0.09$0.06-$0.03$0.06$145.07 million$44.68 million3/10/2026Q4 2025ADCTADC Therapeutics-$0.32-$0.04+$0.28-$0.04$22.29 million$23.06 million2/24/2026Q4 2025FULCFulcrum Therapeutics-$0.31-$0.31N/A-$0.31N/AN/A2/14/2026Q4 2025ADCTADC TherapeuticsN/A-$0.09N/A-$0.04N/A$23.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AKMDAKamada$0.192.26%N/A54.29%N/APYXSPyxis OncologyN/AN/AN/AN/AN/ALatest PYXS, KMDA, FULC, and ADCT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/11/2026KMDAKamadaannual$0.253.05%3/23/20263/23/20264/7/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.31FULCFulcrum TherapeuticsN/A34.3334.33KMDAKamadaN/A4.072.28PYXSPyxis OncologyN/A3.413.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%FULCFulcrum Therapeutics89.83%KMDAKamada20.38%PYXSPyxis Oncology39.07%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%FULCFulcrum Therapeutics7.00%KMDAKamada36.10%PYXSPyxis Oncology10.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableFULCFulcrum Therapeutics10066.63 million61.97 millionOptionableKMDAKamada36057.51 million36.75 millionOptionablePYXSPyxis Oncology6062.85 million56.19 millionOptionablePYXS, KMDA, FULC, and ADCT HeadlinesRecent News About These CompaniesPyxis Oncology Appoints Nelson Azoulay as Chief Business OfficerMay 7 at 4:05 PM | globenewswire.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 7 at 2:54 AM | americanbankingnews.comPyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 7 at 2:46 AM | marketbeat.comWedbush initiates coverage of Pyxis Oncology (PYXS) with outperform recommendationMay 5 at 7:39 PM | msn.comPyxis Oncology (NASDAQ:PYXS) Coverage Initiated by Analysts at WedbushMay 5 at 8:32 AM | marketbeat.comShort Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7%May 1, 2026 | marketbeat.comPyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026April 17, 2026 | globenewswire.comPyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" RatingApril 13, 2026 | marketbeat.comPyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from BrokeragesApril 12, 2026 | marketbeat.comRachel Humphrey Sells 13,896 Shares of Pyxis Oncology (NASDAQ:PYXS) StockMarch 26, 2026 | insidertrades.comPyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Pyxis Oncology (PYXS)February 5, 2026 | theglobeandmail.comPyxis Oncology Appoints Thomas Civik as Interim CEO Following Leadership TransitionFebruary 3, 2026 | quiverquant.comQPyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program ContinuityFebruary 3, 2026 | globenewswire.comRBC Capital Sticks to Its Buy Rating for Pyxis Oncology (PYXS)January 7, 2026 | theglobeandmail.comHC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendationDecember 20, 2025 | msn.comWhy Pyxis Oncology, Inc.’s (PYXS) Stock Is Down 53.39%December 20, 2025 | aaii.comAPyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma TranscriptDecember 18, 2025 | seekingalpha.comPyxis Oncology announces preliminary Phase 1 data for micvotabart pelidotinDecember 18, 2025 | msn.comPyxis Oncology stock plummets after early-stage cancer drug dataDecember 18, 2025 | za.investing.comPyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaDecember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYXS, KMDA, FULC, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$3.72 -0.04 (-0.93%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Fulcrum Therapeutics NASDAQ:FULC$7.05 +0.17 (+2.49%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Kamada NASDAQ:KMDA$8.40 +0.14 (+1.66%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Pyxis Oncology NASDAQ:PYXS$2.46 +0.20 (+8.63%) As of 11:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
